Skip to main content
. 2022 Dec 12;22:929. doi: 10.1186/s12879-022-07896-0

Table 1.

Summary of FDA-approved IL-6 receptor antagonist

Generic name Brand name Indication Year of approval by FDA
Tocilizumab Actemra RA, CRS, sJIA, Giant cell arteritis, COVID-19 2003; tocilizumab was granted an EUA for the treatment of COVID-19 in June 2021
Sarilumab Kevzara RA 2017

RA rheumatoid arthritis, CRS cytokine release syndrome, sJIA systemic juvenile idiopathic arthritis